Logo image of KNW

KNOW LABS INC (KNW) Stock Fundamental Analysis

NYSEARCA:KNW - NYSE Arca - US4992381032 - Common Stock - Currency: USD

0.0856  -0.02 (-20.74%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to KNW. KNW was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of KNW have multiple concerns. KNW does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KNW had negative earnings in the past year.
In the past year KNW has reported a negative cash flow from operations.
KNW had negative earnings in each of the past 5 years.
In the past 5 years KNW always reported negative operating cash flow.
KNW Yearly Net Income VS EBIT VS OCF VS FCFKNW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -419.11%, KNW is doing worse than 97.37% of the companies in the same industry.
Industry RankSector Rank
ROA -419.11%
ROE N/A
ROIC N/A
ROA(3y)-196.65%
ROA(5y)N/A
ROE(3y)-930.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KNW Yearly ROA, ROE, ROICKNW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

KNW does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KNW Yearly Profit, Operating, Gross MarginsKNW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

KNW does not have a ROIC to compare to the WACC, probably because it is not profitable.
KNW has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, KNW has a worse debt to assets ratio.
KNW Yearly Shares OutstandingKNW Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KNW Yearly Total Debt VS Total AssetsKNW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

KNW has an Altman-Z score of -45.55. This is a bad value and indicates that KNW is not financially healthy and even has some risk of bankruptcy.
KNW's Altman-Z score of -45.55 is on the low side compared to the rest of the industry. KNW is outperformed by 91.05% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -45.55
ROIC/WACCN/A
WACC8.18%
KNW Yearly LT Debt VS Equity VS FCFKNW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 0.93 indicates that KNW may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.93, KNW is doing worse than 91.58% of the companies in the same industry.
A Quick Ratio of 0.93 indicates that KNW may have some problems paying its short term obligations.
KNW has a worse Quick ratio (0.93) than 80.53% of its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
KNW Yearly Current Assets VS Current LiabilitesKNW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -16.77% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.15%
EPS Next 2Y-16.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNW Yearly Revenue VS EstimatesKNW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
KNW Yearly EPS VS EstimatesKNW Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KNW reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KNW. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KNW Price Earnings VS Forward Price EarningsKNW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNW Per share dataKNW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15 -0.2

4.3 Compensation for Growth

KNW's earnings are expected to decrease with -16.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.77%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KNW does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KNOW LABS INC

NYSEARCA:KNW (1/29/2025, 8:04:02 PM)

0.0856

-0.02 (-20.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)02-12 2025-02-12
Inst Owners5.3%
Inst Owner ChangeN/A
Ins Owners24.65%
Ins Owner Change0%
Market Cap9.25M
Analysts80
Price Target1.02 (1091.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -419.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.65%
ROA(5y)N/A
ROE(3y)-930.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z -45.55
F-Score1
WACC8.18%
ROIC/WACCN/A
Cap/Depr(3y)147.16%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y-16.15%
EPS Next 2Y-16.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.63%
OCF growth 3YN/A
OCF growth 5YN/A